Rasm

Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise

Retrieved on: 
金曜日, 5月 17, 2024
Probability, RAS, Patient, Metabolism, ADME, Rasm, Glioblastoma, NDA, MAPK, Clinical trial, Neoplasm, BIC, ASCO, CRC, ID, Pharmaceutical industry

SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced it has entered into exclusive license agreements for two preclinical RAS programs—a potential best-in-class pan-RAS molecular glue (ERAS-0015) and a potential first-in-class pan-KRAS inhibitor (ERAS-4001)—and provided a pipeline update. ERAS-0015 and ERAS-4001 are highly potent, orally bioavailable molecules with complementary RAS inhibitory mechanisms that have the potential to address unmet needs in nearly 2.7 million patients who are diagnosed annually globally with RAS-mutant (RASm) tumors, of which over 2.2 million patients are diagnosed with KRAS-mutant (KRASm) tumors.

Key Points: 
  • As separately announced, Erasca has priced an equity offering of $160 million with a high quality group of new and existing healthcare-focused investors.
  • “We’re thrilled to add ERAS-0015 and ERAS-4001 to our pipeline.
  • This is undoubtedly a challenging time for our highly talented employees, particularly those affected by these changes.
  • The live webcast and replay may be accessed by visiting Erasca’s website at Erasca.com/events .

Inspirna Partners with Merck KGaA, Darmstadt, Germany, to Accelerate Global Development of Ompenaclid (RGX-202)

Retrieved on: 
木曜日, 1月 4, 2024
Research, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, SLC6A8, Merck Group, CRC, ESMO, Survival, Rasm, Health care, Colorectal cancer, FOLFIRI, Progression-free survival, Congress, Randomized controlled trial, Bevacizumab, Creatine, Merck, RAS, Patient, Safety, Head, Therapy, Pharmaceutical industry

“The data to date validates our belief in ompenaclid as a potential first-in-class therapy for advanced colorectal cancer and underscores the power of our proprietary target discovery platform RNA-DRIVEr™.

Key Points: 
  • “The data to date validates our belief in ompenaclid as a potential first-in-class therapy for advanced colorectal cancer and underscores the power of our proprietary target discovery platform RNA-DRIVEr™.
  • Furthermore, the parties agreed to collaborate on Inspirna’s SLC6A8 follow-on compounds for which Inspirna will retain US co-development and co-commercialization rights.
  • Ompenaclid was well-tolerated, with no dose-limiting toxicities observed in the dose-escalation cohort and combination safety profile comparable to FOLFIRI plus bevacizumab backbone treatment.
  • Inspirna has initiated a Phase 2 double-blind randomized controlled trial in 2L RAS mutant advanced or metastatic mCRC comparing ompenaclid versus placebo plus FOLFIRI and bevacizumab.

Inspirna Announces Clinical Data from Phase 1b/2 Study of Ompenaclid (RGX-202) in Advanced Colorectal Cancer at ESMO Congress 2023

Retrieved on: 
月曜日, 10月 23, 2023
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Bevacizumab, Neoplasm, PRS, MTD, RAS, Annals of Oncology, ESMO, Principal investigator, Therapy, Assistant, Infrared spectroscopy correlation table, FOLFIRI, MOS, Congress, European Society for Medical Oncology, SLC6A8, BID, Rasm, HIV disease progression rates, Poster, BEV, CRC, Index, KOL, Cedars-Sinai Medical Center, ORR, RECIST, Annals, Apoptosis, Patient, Randomized controlled trial, Mutation, PR, Pharmaceutical industry, Medicine

The Phase 1b/2 study of ompenaclid in combination with FOLFIRI/BEV in second-line (2L) advanced or metastatic CRC patients has completed enrollment, with an ongoing follow up period.

Key Points: 
  • The Phase 1b/2 study of ompenaclid in combination with FOLFIRI/BEV in second-line (2L) advanced or metastatic CRC patients has completed enrollment, with an ongoing follow up period.
  • The primary endpoint of the study is to determine maximum tolerated dose (MTD), objective response rate (ORR), and treatment-emergent adverse events (TEAEs).
  • The abstract is published in the ESMO Congress 2023 Abstract Book, a supplement to the official ESMO journal, Annals of Oncology.
  • Title: Phase 1b/2 study of ompenaclid (RGX-202-01), a first-in-class oral inhibitor of the creatine transporter SLC6A8, in combination with FOLFIRI and bevacizumab (BEV) in RAS mutated (RASm) second-line (2L) advanced/metastatic colorectal cancer (mCRC)

Inspirna to Present Clinical Data from Phase 1b/2 Study of Ompenaclid (RGX-202) in Advanced Colorectal Cancer at ESMO Congress 2023

Retrieved on: 
月曜日, 10月 16, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Congress, Index, HIV disease progression rates, Bevacizumab, FOLFIRI, Apoptosis, Rasm, ORR, Therapy, MTD, KOL, SLC6A8, RAS, CRC, ESMO, European Society for Medical Oncology, BEV, Patient, Pharmaceutical industry

Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class cancer therapeutics, announced today that data from the ongoing Phase 1b/2 study of ompenaclid (RGX-202) in combination with FOLFIRI and bevacizumab (BEV) in RAS-mutated (RASm) advanced or metastatic colorectal cancer (CRC) will be presented at the European Society for Medical Oncology (ESMO) Congress 2023 being held October 20-24, 2023 in Madrid, Spain.

Key Points: 
  • Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class cancer therapeutics, announced today that data from the ongoing Phase 1b/2 study of ompenaclid (RGX-202) in combination with FOLFIRI and bevacizumab (BEV) in RAS-mutated (RASm) advanced or metastatic colorectal cancer (CRC) will be presented at the European Society for Medical Oncology (ESMO) Congress 2023 being held October 20-24, 2023 in Madrid, Spain.
  • Ompenaclid triggers tumor regressions in CRC patients by inducing apoptosis of tumor cells.
  • The Phase 1b/2 study of ompenaclid in combination with FOLFIRI/BEV in second-line (2L) advanced or metastatic CRC patients has completed enrollment, with an ongoing follow up period.
  • The primary endpoint of the study is to determine maximum tolerated dose (MTD), objective response rate (ORR), and treatment-emergent adverse events (TEAEs).